Anaptysbio (ANAB) Profit After Tax Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Profit After Tax Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -12.04% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 94.83% |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | -34.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -34.28% |
| Dec 31, 2025 | 328.94% |
| Sep 30, 2025 | 146.17% |
| Jun 30, 2025 | 17.21% |
| Mar 31, 2025 | 10.16% |
| Dec 31, 2024 | 48.39% |
| Sep 30, 2024 | 11.95% |
| Jun 30, 2024 | -17.10% |
| Mar 31, 2024 | 0.72% |
| Dec 31, 2023 | -64.55% |
| Sep 30, 2023 | -4.66% |
| Jun 30, 2023 | -22.40% |
| Mar 31, 2023 | -22.07% |
| Dec 31, 2022 | 21.70% |
| Sep 30, 2022 | -432.86% |
| Jun 30, 2022 | -7,488.34% |
| Mar 31, 2022 | -99.61% |
| Dec 31, 2021 | -198.13% |
| Sep 30, 2021 | 72.42% |
| Jun 30, 2021 | 98.01% |